

**IFPA**

GLOBAL LEADER IN FIGHTING  
PSORIATIC DISEASE

**IFPA org no 802428-5986**

**Annual  
Accounts  
2023**

## Contents

Director’s Declaration 2023 .....	3
Purpose of the Federation .....	3
Vision.....	3
Mission.....	3
Goals .....	3
Values .....	4
Priority issues.....	4
Year 2023.....	5
Theme of the year: Universal Health Coverage .....	5
Governance .....	5
General Assembly.....	5
Board Meetings .....	6
Secretariat.....	6
Members.....	6
IFPA Member Meeting 2023 .....	6
Webinars .....	7
IFPA Accelerator Program.....	7
IFPA Funds.....	8
Solidarity Fund.....	8
IFPA Start-Up Fund .....	8
Project Rare GPP .....	8
UPLIFT Innovation Program .....	9
Communications.....	9
Communication channels .....	9
IFPA Update and Newsletters .....	9
Website .....	9
Social media.....	10
World Psoriasis Day.....	10
Advocacy and Policy .....	11
IFPA Coalition .....	11
Resources .....	11
Relationship with international policy bodies.....	11
IFPA’s network in advocacy .....	12
IFPA Forum .....	12

Science .....13

    External science events .....13

    IFPA Conference .....14

    The Global Psoriasis Atlas (GPA) .....14

    MySkin ..... 15

    Psoriasis and Beyond ..... 15

Projects 2023..... 15

    IFPA Ambassadors ..... 15

    All the Colors We Are ..... 16

Corporate Partners ..... 16

Administration report.....17

    Profit and loss account ..... 18

    Profit and loss account ..... 19

    Costs per activity..... 20

    Costs per activity..... 21

    Costs per activity..... 22

    Costs per activity..... 23

    Costs per activity..... 24

    Costs per activity..... 25

    Costs per activity..... 26

    Balance sheet .....27

    Notes ..... 28

    Notes ..... 29

    Notes ..... 30

    Signatures .....31

# Director's Declaration 2023

Founded in 1971, IFPA is the international federation of psoriatic disease associations. We are the psoriatic disease community. Our members represent over 60 million people living with psoriatic disease. Together, we advocate for progress.

## Purpose of the Federation

IFPA is the global voice dedicated to advancing psoriatic disease policy. IFPA is the trusted convener of psoriatic disease stakeholders across sectors and geographies, partnering to strengthen national and regional capacity and leadership. IFPA works with others to generate and share evidence to inform change that can address unmet needs for people living with psoriatic disease.

- **Legitimacy to represent people living with psoriatic disease:** IFPA is the only organization that brings a unified global voice of people living with psoriatic disease to the global agenda.
- **History and track record in the psoriatic disease community:** IFPA has been unifying the psoriatic disease community and has a proven track record of elevating psoriatic disease onto the global agenda.
- **Independence and integrity:** Decisions are exclusively driven by the needs of the people living with psoriatic disease.

## Vision

A future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities.

## Mission

Unite, strengthen and lead the global psoriatic disease community to improve the lives of all people affected by psoriatic disease.

## Goals

**Ensure global representation:** Boost the voices of everyone living with psoriatic disease, everywhere.

**Lead global advocacy:** Fight for the interests of people affected by psoriatic disease. Demand representation on global health and development agendas.

**Strengthen member capacity:** Strengthen IFPA members. Raise national support for people living with psoriatic disease.

**Share knowledge:** Close the gap between knowledge and action. Trigger breakthroughs for people living with psoriatic disease.

**Unite stakeholders:** Build alliances. Transform global, regional, and national collaboration.

The interrelated goals are equally important and support each other. The strategic goals are further broken down in different activities with performance indicators set for 2024 and for 2030.

In addition to goals, four core values are identified, as well as a number of priority issues, those cross-cutting issues that influence the strategic goals and vary in relevance and importance. The priority issues identified by IFPA, and its stakeholders, very much reflect the issues set out in the WHO Global Report on Psoriasis in 2016.

## Values

**Person-centered:** Ensure that people living with psoriatic disease are at the heart of everything IFPA does.

**Collaborative:** Work together and openly with members and partners.

**Accountable:** Be responsible for all actions

**Bold:** Have the confidence and courage to lead the global psoriatic disease community.

## Priority issues

**Equal access to treatment, specialists and individualized care:** People living with psoriatic disease require access to appropriate treatment and care, including trained healthcare professionals and medicines. However, inadequate access to healthcare is a challenge in many countries across the world.

**Early diagnosis of psoriatic disease:** People living with psoriatic disease can experience unnecessary suffering, irreversible deformities of the joints and disability due to late diagnosis and lack of appropriate treatment. One standard global guideline to help promote early diagnosis of and appropriate treatment for people living with psoriatic disease.

**Making healthcare providers aware of psoriatic disease:** Lack of adequate training for healthcare practitioners and providers results in low awareness of psoriatic disease. Increased awareness and understanding of psoriatic disease among those responsible for providing care can help facilitate early diagnosis and appropriate treatment.

**Stop stigma:** People with psoriatic disease still experience stigmatization and discrimination. Public misconceptions about psoriasis, for example the myth that it is a contagious disease, result in people with psoriatic disease being excluded from everyday life and foster low self-esteem, depression and even suicidal thoughts.

**Change the perception of psoriatic disease and call for consensus on categorizing severity:** Psoriatic diseases are complex and unpredictable conditions with varied manifestations and associated diseases that affect individuals differently. The misperception that psoriatic disease is a mere skin condition and the lack of consensus on categorizing the severity levels of the condition can lead to inadequate treatment and care.

**Multidisciplinary care:** People living with psoriatic disease require access to multidisciplinary care to identify and manage common comorbidities that already exist or may develop, including cardiovascular and metabolic diseases (such as diabetes) and psychological conditions. Multidisciplinary care teams include primary care physicians, dermatologists,



rheumatologists, psychologists, psychiatrists, pediatricians, cardiologists, and endocrinologists.

**Link psoriatic disease and mental health:** Psoriatic disease causes great physical, emotional, and social burdens, all of which may impair an individual's quality of life and be psychologically devastating. Increased awareness and focus on the link between psoriatic disease and mental health can help improve quality of life and wellbeing for people living with psoriatic disease.

**Join forces with family and community:** Psoriatic disease affects relationships at home, school, and work, as well as intimate relationships. Community support, caretakers, and families should be included in the fight against psoriatic disease.

# Year 2023

## Theme of the year: Universal Health Coverage

Throughout the year, IFPA committed to advancing Universal Health Coverage (UHC), to ensure that everyone, regardless of their socio-economic background, has access to essential healthcare services without facing financial hardship. By addressing barriers and promoting preventive measures, the goal was to not only improve health outcomes but also foster a world where the right to health is universally acknowledged and protected.

IFPA announced comprehensive resources on UHC, which served as valuable tools, offering insights, guidelines, and strategies to further the cause of UHC. The theme acted as a red thread, uniting IFPA's advocacy priorities and project choices for the year, as well as World Psoriasis Day. IFPA representatives also participated in the UN High Level Meeting on UHC in New York and at different interviews, video recordings, podcasts, conferences and presentations on the theme.

Below follows a description of IFPA's activities and achievements during the year.

## Governance

### General Assembly

The General Assembly, consisting of IFPA's full Members, is the highest decision-making body of IFPA. The meeting of the General Assembly is held every three years, with the next to be held in 2025.

The General Assembly elects a Board composed of seven members. The Board governs IFPA in accordance with its objectives and its regulatory and statutory obligations. The Board represented by its President shall have the overall responsibility for ensuring the well-functioning of IFPA and compliance by the organization until a new Board is elected at next General Assembly. An extraordinary meeting of the General Assembly can be convened upon the recommendation of the Board or one-third of the full members.

## Board Meetings

In 2023 the IFPA Board had ten (10) Board meetings, of which three (3) were physically conducted.

## Secretariat

During 2023 the IFPA Secretariat consisted of the:

- Executive Director
- Finance & Administration Manager
- Marketing & Communications Manager – expanded role
- Community Manager – new role
- Policy & Advocacy Manager
- Fundraising Manager – new role
- Scientific Officer
- Global Communicator – new role

The number of full-time staff positions at the Secretariat was 8 (7). In addition to the above staff positions, IFPA also had two interns in the spring: one focusing on member education and science and the other one focusing on marketing.

## Members

This year new members were welcomed from China, Hungary and Romania. By December 31, 2023, IFPA had 61 national member organizations in 57 countries and 3 regional member organizations. One member was lost in 2023 because winding up of the association.

## IFPA Member Meeting 2023

The Member Meeting was held at ParkRoyal on Kitchener Road in Singapore on July 2 and brought together 92 onsite patient advocates and psoriatic disease stakeholders from all over the world. The meeting consisted of four sessions:

- Global Health Advocacy: Universal Health Coverage & 10 year after the Resolution
- One IFPA: The Member Community
- National Achievements
- Global Psoriasis Atlas (GPA)
- Celebrating Anniversaries

The meeting was followed by a dinner for members and stakeholders.

## Member Survey

In IFPA's global strategy, 'Strengthen member capacity' is one of the five main goals. It is therefore important for IFPA to continually collect reports from national and regional members around the world. These reports help us understand the global impact of our organization on the lives of people living with psoriatic disease. They also inform our strategy to continue improving our organization.

The 2023 Member Reporting was conducted December 2023 - January 2024 and organized into three areas:

- Feedback on IFPA activities in 2023
- Member actions contributing to IFPA's strategic goals
- Input to IFPA's 2024 activities

42 members reported. Member satisfaction is crucial to IFPA and by 2024 we set out to have a satisfaction rate of 4+ out of 5. The member satisfaction rate for 2023 was 4.2 (3.8).

More details from the member reporting can be found in the [“IFPA Member Report 2023”](#).

Notable impactful actions by our members from this year include the passing of [Canada Disability Benefit Act](#), the launching of EUROPSEVATORY in Europe and the completion of the Chinese online film ‘Hello, My Psoriasis Lover’.

## Member Portal

The Member Portal is a resource to meet the members' needs that is:

- A knowledge hub hosting the latest psoriatic disease research
- A collaborative space for communication between members
- A learning center to continue building capacity and skills
- A place to showcase national work
- A library of resources

During 2023, continued efforts were made to create a user-friendly community platform.

## Webinars

IFPA Webinars are open live for everyone, and on demand for our members through the IFPA Member Website. One webinar was conducted during the year, a joint virtual workshop with IFPA's partner IDEOM on the new symptom-measurement tool, MSK-Q.

## IFPA Accelerator Program

The Accelerator program is one of our four flagship programs, a training program that supports organizations to expand their work and guides new advocates in establishing patient associations.

The program aims to:

- Accelerate the growth of IFPA
- Leverage the skills and capacities of selected member associations in each region
- Strengthen regional alliances and facilitate best practice sharing within regions

In 2023, trainings were created on topics like:

- Board Training
  - Promoting current projects
- Member Trainings
  - Project Development
  - Community Mobilization
  - Start-up Training for New Patient Organizations
- Ambassador Training
  - Project Development

## IFPA Funds

With different funds IFPA support efforts worldwide to strengthen patient organization's ability to act. Read more on [IFPA Funding page](#).

### Solidarity Fund

The IFPA Solidarity Fund was created to address the funding gap faced by many of IFPA's members, by awarding grants to support advocacy, education and awareness-raising in psoriatic disease. During 2023, the Solidarity Fund had one call for application. 6 out of 6 applying organizations were elected to share 17,521 EUR.

- Epidermia, Greece – Tips for Mental Wellbeing When Living with Psoriatic Disease
- Hong Kong Psoriasis Association – Researching the Economic Burden
- Psoriasis Association of Kenya – Starting on the Right Path with Psoriatic Disease
- Persatuan Psoriasis Malaysia – Raising Awareness of Scalp Psoriasis Among Hairdressers
- SAPSA, South Africa – Health Literacy for Improved Health Outcomes
- PsorViet, Vietnam – Communication Pack for Psoriasis Awareness

### IFPA Start-Up Fund

The IFPA Start-Up Fund was created in 2023 to support individuals or groups who reside in a country where there doesn't exist a patient association, and who has the ability to start one. For this reason, the Start-Up funding is connected to specific projects, Start-Up projects, with the purpose of starting new patient associations.

In 2023, Start-Up projects were initiated in Afghanistan and Rwanda.

### Project Rare GPP

The Project Rare GPP fund is an opportunity for patient organizations to reach those in their region living with GPP (Generalized Pustular Psoriasis). National patient organizations are crucial to the fight against psoriatic disease, and often lack resources to carry out all the projects they wish for. With the financial assistance from this fund, they can realize some of these projects.

During 2023, the Fund had two calls for application, where applying organizations could share a total of 100,000 EUR.

First round was closed March 15, 4 out of 12 project applications were elected:

- Acción Psoriasis Spain – Rare GPP Campaign
- EUROPSO – Wellness Program for Individuals Living with GPP
- Psoriasispatiënten Nederland – Modular GPP Project
- Psoriasis Philippines – GPP Care

Second round was closed August 31, 5 out of 13 project applications were elected:

- FUNDAPSO Colombia – Characterization of GPP Patients in Colombia
- EUROPSO – Wellness Program for Individuals Living with GPP
- Persatuan Psoriasis Malaysia – GPP Navigators
- Psoriasispatiënten Nederland – Connecting GPP Patients
- SAPSA South Africa – Data Collection & Producing Educational Materials



## UPLIFT Innovation Program

Since 2021, IFPA and Amgen have issued a global call for actionable solutions to address a challenge that people living with psoriatic disease and healthcare providers continue to face. The UPLIFT Innovation Program promotes an open dialogue about a patient's health and treatment goals and strengthens cooperation. Organizations around the world are awarded donations for projects that promote an open dialogue about a patient's health and treatment goals and strengthens cooperation.

2023's question was: How can we boost collaboration between people living with psoriatic disease and their healthcare providers to establish and achieve shared treatment goals?

In October, 4 organizations, out of 17, were awarded donations to execute their vision to respond to this question, to the total amount of 70,000 USD.

- National Psoriasis Foundation, USA – 5 different format resources for improved healthcare provider and patient collaboration
- Psoriasis Association of Taiwan – Workshop series for healthcare providers to learn what is left unsaid during appointments
- APAPP, Puerto Rico – Specialist referral system to direct people living with psoriatic disease to the correct healthcare providers
- APAPSO Peru – Podcast featuring conversations between healthcare providers and patients

# Communications

## Communication channels

### IFPA Update and Newsletters

IFPA continued with the IFPA update, an internal newsletter to communicate more frequently with IFPA members and keep them informed of developing projects and opportunities.

IFPA sent two Newsletters to 107 external recipients such as stakeholders, partners and others. These illuminated such topics as information about the IFPA Conference (7<sup>th</sup> WPPAC), World Psoriasis Day, IFPA's film about Access to Care, resources on Universal Health Coverage, Psoriasis and Beyond data exploration tool, and other actions in 2023.

### Website

In 2023, changes in Google policies combined with updates to our analytics software introduced alterations in the way data was collected, processed, and interpreted. The changes make a direct comparison of 2022 and 2023 data impossible. Considering the importance of tracking trends and performance over time, IFPA is adapting to the changes to ensure the accuracy and reliability of data analysis moving forward.

We can provide some analytic insights for 2023. Page views are estimated to 40,809. The top five countries frequenting the IFPA website being the USA, UK, India, Singapore, and Sweden. The most visited web pages include the Homepage, World Psoriasis Day, IFPA Conference, Resources & Tools, and World Psoriasis Day campaign materials, underlining the diverse interests of visitors, from general information to specific events and campaign details.



**Social media**


In 2023 IFPA focused on creating informative content, meaningful connections and engaged communities on our social media platforms.

Notable highlights were the “Access to Care” film, World Psoriasis Day conversations, a video testimonial by an IFPA Ambassador navigating life with psoriatic disease, IFPA Forum Asia 2023 discussions.

Social media followers across the various platforms at the end of 2023 (2022):

- 3K on Instagram (2.3K)
- 1.2K on LinkedIn (0.9K)
- 6.4K on Twitter (7.2K)
- 14K on Facebook (14K)
- 0.9K on TikTok (1K)
- 0.4K subscribers on YouTube (n/a)

**World Psoriasis Day**



World Psoriasis Day (WPD) is the annual day dedicated to people living with psoriatic disease. WPD is celebrated on October 29, with the overall aim of:

- Raising awareness about the severity of the disease and the everyday challenges faced by people living with psoriatic disease
- Spreading information about psoriatic disease, refuting common misconceptions and increasing knowledge among people living with the condition
- Improving access to treatment by targeting health ministers, governments and decision-makers
- Creating a united platform to empower people living with psoriatic disease

World Psoriasis Day provides a unique opportunity for IFPA to take action, drive advocacy, and demonstrate leadership among multiple stakeholder groups. IFPA uses World Psoriasis Day to mobilize enthusiasm for a shared theme and goal.

World Psoriasis Day 2023 was marked by a global commitment to promoting inclusivity and accessibility for individuals living with psoriatic disease. The theme "Access for All" emphasized the importance of ensuring that individuals with psoriatic disease, regardless of their geographical location, economic status, or other barriers, have equitable access to quality healthcare and resources. The day served as a platform to address the disparities in the diagnosis, treatment, and overall management of psoriasis, with a focus on inclusivity and equality. Learn more in IFPA's [World Psoriasis Day 2023 Impact Report](#).

The press release "World Psoriasis Day 2023: Access for All" had 486.6K recorded views with a potential reach of 1.6B.

## Advocacy and Policy

### IFPA Coalition

By collaborating across borders, sectors and disease areas, IFPA uses the Coalition to generate support to implement the recommendations outlined in the Global Report on Psoriasis, developed by the World Health Organization in 2016. To reach its goal to lead global advocacy, IFPA has defined a triple A (AAA) Action plan: Act, Amplify, and Align. The Coalition convened four times in 2023: March (virtual), July, October and December (virtual). During these meetings, the main initiatives in advocacy were discussed, namely:

- The IFPA Forum Asia, its preparation and the results from the Forum
- The resources developed for universal health coverage
- IFPA's participation in United Nations' meetings and the statements submitted
- The follow-up to the IFPA Forum Europe

Coalition members gave helpful input and contributions to discussions to further amplify IFPA's advocacy work. In 2023, the IFPA Coalition counted 15 members from civil society, industry, and medical professionals' organizations.

### Resources

IFPA developed and launched several resources linked to the theme of universal health coverage (UHC):

- A template to write to politicians
- A manuscript to record videos on universal health coverage
- The report "Strengthening global commitments to UHC for psoriatic disease"
- A one-pager "Universal health coverage-focus approaches key to enabling psoriatic disease care"
- A toolkit on the 2023 political declaration on UHC and psoriatic disease

### Relationship with international policy bodies

IFPA representatives followed the 76th World Health Assembly remotely as the limited number of seats available for the in-person event impeded our participation. IFPA contributed to the proceedings of the assembly by joining in the submission of a statement together with other organizations, as part of the Global Health Council delegation.

IFPA connected to a new representative in the WHO headquarters, had three meetings with the new contact and agreed on a project to conduct in 2024.



## IFPA's network in advocacy

IFPA renewed its membership in the International Alliance of Patients' Organizations (IAPO), the Global Health Council and the NCD Alliance, in which IFPA is an active member of the Inclusive Agenda program, a project promoting inclusivity in the non-communicable disease sphere. IFPA is also a member of the Civil Society Engagement Mechanism for Universal Health Coverage (CSEM), CoNGO and Rare Diseases International.

IFPA continued its collaboration with the International Alliance of Dermatology Patient Organizations (IADPO/GlobalSkin) and is member of the IADPO-led World Skin Health Coalition.

IFPA continued the collaboration with the International Psoriasis Council (IPC) and had regular meetings and a few activities together. A letter of Commitment was also signed with IPC and International League of Dermatological Societies (ILDS) to affirm the shared dedication and collaborative efforts towards advancing the understanding, treatment and support of individuals affected by psoriatic disease and other dermatological conditions worldwide.

IFPA signed a letter of collaboration with the International Dermatology Outcome Measures (IDEOM) to advance research and enhance the lives of individuals living with psoriatic disease. With a shared vision of making a positive impact on this community, both organizations recognize the value of joining forces to advance research, education and support initiatives; bringing together global networks of patients in the real and digital world with tools and techniques.

## IFPA Forum

The IFPA Forum is a Flagship program of IFPA designed to put the needs of people living with psoriatic disease at the center of the policy discourse at the regional level.

IFPA's second Forum targeted Asia. A Briefing Book and four theme briefs were developed to investigate four pressing needs for people living with psoriatic disease in Asia and Western Pacific. The Briefing Book is available in 6 languages.

The Forum was held in Singapore on July 3, 2023, and brought together 118 patient advocates, policymakers and allies from industry and civil society to speak up for psoriatic disease in Asia and find solutions to the needs outlined in the briefing book. Another resource launched at the Forum was the Psoriatic Disease Response Index: Western Pacific Region, an analysis on how five health systems in the region manage psoriatic disease in light of the recommendations put forward in the 2016 WHO Global Report on Psoriasis. In fall a press release on the Psoriatic Disease Response Index had 163.4K recorded views, and a potential reach of 1B.

The IFPA Forum Europe Action Playbook, a resource developed as follow-up to the IFPA Forum Europe (2022), was presented in a meeting with all European members during the European Psoriasis Week (end of May).

The outcome was a roadmap, action plan and playbook based on the discussions from the Forum, and an active collaboration with the Asian regional member organization PsorAsia. In December we started to develop a toolkit that will support the members to implement the actions from the roadmap.

## Science

'Share knowledge' is one of IFPA's strategic goals. By staying informed on the latest research and sharing knowledge IFPA contribute to closing the gap between knowledge and action, which is one of the challenges related to psoriatic disease. This is relevant for treatment and applies to IFPA's priority issues such as timely diagnosis, stigma, discrimination, equality and general understanding.

### External science events

IFPA participated in Scientific dermatology and rheumatology conferences during the year. We contributed with lived experience, spoke up for patient centricity, UHC, diversity, holistic care and much more. This year IFPA used the space in the booths to market the upcoming IFPA conference and also to raffle off free tickets.

#### **AAD Annual Meeting, New Orleans, March 17-21**

The 2023 Annual Meeting of the American Academy of Dermatology took place in New Orleans in March. Over 17,000 registrants showed up at the Ernest N. Morial Convention Center.

#### **PANLAR, Rio de Janeiro, April 26-29**

The 25th Pan American Congress of Rheumatology (PANLAR 2023) held at Windsor Oceanico Hotel had more than 2,500 delegates.

#### **EULAR, Milan, May 31-June 3**

The European League Against Rheumatism (EULAR) Congress at MiCo Convention Center had over 12,000 registrations. IFPA took the opportunity to showcase the work and resources we have developed on Psoriatic Arthritis (PsA) and interact with key opinion leaders, EULAR patient engagement teams and delegates at meetings and in the booth. One of IFPA's Ambassadors broadcasted a podcast on Psoriatic Arthritis (PsA) with 200 listeners and 140 downloads, as well as a successful launch event with over 3,000 engagements on social media.

#### **WCD, Singapore, July 4-8**

The World Congress of Dermatology (WCD), organized by the ILDS, is held every 4 years. Over 12,000 persons attended the Suntec Singapore Convention & Exhibition Centre. IFPA had a booth in the Patient Village and interacted with delegates around the world. IFPA Board and Staff was invited as speakers to a number of symposia and held a total of 15 presentations. IFPA also presented the patient perspective together with IPC in their symposium. IFPA organized a Joint Reception at the World Congress of Dermatology in Singapore, "From Global to Local" together with The International Psoriasis Council (IPC) and the Global Psoriasis Atlas (GPA), in partnership with the Burma Skincare Initiative (BSI) and PsorAsia. Through such collaborative initiatives, the global psoriatic disease community continues to push boundaries, break barriers, and strive for a future where all people living with psoriatic disease enjoy good health and wellbeing.

#### **IPC Think Tank, Faroe Islands, September 8**

IFPA President and Vice President were invited to the IPC Think Tank and Gunnar Lomholt Symposium in the Faroe Islands. We contributed with the patient perspective in discussions around genetics, comorbidities, treatment strategies and much more.



**EADV, Berlin, October 11-14**

The European Academy of Dermatology and Venereology Congress (EADV) at Messe Berlin congress center had over 15,500 delegates. IFPA attended sessions and co-hosted the joint patient booth provided by EADV. Ahead of EADV, IFPA as member of the EADV Task Force actively collaborated to expand patient organization participation at the congress.

**ACR, San Diego, November 10-15**

American College of Rheumatology (ACR) Convergence took place at the San Diego Convention Center with more than 13,00 attendees. IFPA had a booth in the nonprofit area of the exhibition and interacted with key opinion leaders in rheumatology.

**APLAR, Chiang Mai, December 7-11**

The 25<sup>th</sup> Asia-Pacific League of Associations for Rheumatology (APLAR) Congress was held at Chiang Mai International Exhibition and Convention Centre with more than 1,500 participants. IFPA had a booth at the congress and a lot of focus was put on marketing the upcoming IFPA Conference.

## IFPA Conference

By conducting the multidisciplinary IFPA Conference on psoriatic disease every third year, since 2006, IFPA drives global scientific research.

The 7<sup>th</sup> IFPA Conference will take place **June 27-29, 2024**, with the theme:

**Uncovering the broad spectrum of psoriatic disease.**

Scientific Executive Committee:

- Chairperson - Prof. April Armstrong
- Co-Chair in Rheumatology - Prof. Laura Coates
- Co-Chair in Dermatology - Prof. Ulrich Mrowietz
- Secretary - Barbra Bohannan

The planning for the Conference, addressing psoriasis and psoriatic arthritis, continued during the year. Registration opened on November 1, with a connected press release with 21.2K recorded views and a potential reach of 1.1B.

## The Global Psoriasis Atlas (GPA)

The Global Psoriasis Atlas is an international project launched in 2016 by IFPA, International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC). It has made incredible progress and is delivered by global experts and an academic project team led by the University of Manchester. The vision is that the GPA will become the leading epidemiological resource globally on psoriasis providing the common benchmark on the burden of psoriasis in all countries and regions throughout the world. The Atlas will seek to: drive continuous improvement in understanding the natural history of psoriasis; uncover how it affects the individual and society; understand how healthcare can be improved for those living with the disease.

The GPA website is the first-ever comprehensive online epidemiological resource database tool. It contains data on the number of psoriasis cases, healthcare data and looks in depth at the experiences and faces behind people living with psoriasis.



In 2023 the Global Psoriasis Atlas advanced epidemiological data with:

- 6 publications
- The GPA website translated into Arabic and Spanish
- A field study to the East Cape of South Africa in December

Further information is available on [www.globalpsoriasisatlas.org](http://www.globalpsoriasisatlas.org).

## MySkin

In 2023, the successfully completed project known as PsoProtect pivoted towards a new research question. Harnessing the global network from the original project, IFPA joined the same research groups and patient organizations to launch a new study called MySkin. MySkin is a longitudinal study seeking to understand disease trajectory and how and why psoriasis changes over time. With the support of IFPA, the study reaches out to the patient community every three months to register their disease progression in a self-reporting portal. In the first year, the project was launched in the UK. Eventually, the study will be expanded to include other parts of the globe as well.

## Psoriasis and Beyond

Psoriasis and Beyond is a joint research initiative between IFPA, 16 national psoriasis organizations and Novartis Pharma AG. The study is overseen by a Steering Committee of patient advocates, dermatologists and rheumatologists.

By understanding the patient experience, including patient awareness of their own disease, our community will be better equipped to design meaningful interventions. The results of the study are hosted on IFPA's website for easy access to patient advocates.

In 2023 IFPA continued to integrate the data in its evidence-based policy advocacy discussions, focusing on the worldwide gaps identified by the study to inform which long-term strategic questions to address. Following publication of the global manuscript, France, India and the US have already published results reflecting the national reality of patients at global medical congresses. Canada, Japan and the US are on the verge of submitting manuscripts co-authored with the national patient organization representatives, describing their respective results to peer-reviewed journals. This means making more data available for inclusion in evidence-based policy advocacy discussions with decision makers. Hosted on [IFPA's website](#), an online educational portal was created to serve as an ongoing broader educational forum for psoriatic disease.

## Projects 2023

### IFPA Ambassadors

During the years, IFPA continuously received requests to contribute patient testimonials, survey participants, and stars for photo and video assets. Unfortunately, IFPA often struggled to find participants available, with thoughtful messaging, representing the full spectrum of people living with psoriatic disease and their caregivers in terms of race, age, body type, gender, and severity of disease.

Through the Ambassador Training program IFPA have recruited a group of 16 ambassadors and given them training on advocacy messaging. Aims of the program are to unite a team of



skilled ambassadors, reliable and ready to speak up for psoriatic disease and its comorbidities in the global arena. Their expert perspectives boost the diverse needs and experiences of people living with psoriatic disease, everywhere.

In 2023 the Ambassadors:

- Received training on project development for awareness raising
- Presented their stories at conferences and on panels
- Directed personal initiatives to address universal health coverage
- Appeared in the film Psoriatic Disease Reflections: A Right to Health
- Collaborated for World Psoriasis Day
- Spoke up at IFPA Forum
- Served on steering committees and participated in projects with civil society organizations and industry partners to raise awareness of patient priorities globally

## All the Colors We Are

IFPA's project addressing diversity and inclusion was launched in November 2022. IFPA Members and Ambassadors from around the world submitted photos of visible psoriatic disease to the virtual library. These images are available for free download to raise awareness of psoriatic disease on every skin. In 2023, IFPA engaged with our members in Singapore on the project, partnered with IPC for a workshop on skin of color and partnered with GPA to start working on a skin of color atlas. The database to date has 450 images and 15 stories.

## Psoriatic Arthritis Awareness

In 2023, IFPA intensified the efforts of increasing awareness of Psoriatic Arthritis – a joint manifestation of Psoriatic Disease associated with high burden and significant comorbidities. Recent progress in understanding the course of psoriatic arthritis (PsA) has led to breakthroughs in therapies. Yet the needs of many people living with PsA are still unmet. Through the project, “Good Care for Psoriatic Arthritis” IFPA aims to join forces with rheumatologists and the patient community to raise awareness of new treatment guidelines, and ultimately improve quality of life for people with PsA around the world. The outcome of the project consisted of three educational videos, 16 articles, and one illustration book. It was presented at three congresses: ACR, WCD and EULAR. The project had a global committee existing of member organizations and Ambassadors.

## Corporate Partners

In 2023, IFPA received funding from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Takeda and UCB.

The support covered all from IFPA Partnership Program and Flagship programs to various projects and initiatives within science and advocacy to improve the lives of all people affected by psoriatic disease. Project sponsors are revealed under the project description on IFPA's website.

## Administration report

The Board of IFPA hereby delivers the annual accounts for the full year of 2023. Regarding the result and financial positions, please refer to the following statements.



**President**  
Hoseah Waweru, M.D.  
Nairobi, Kenya



**Vice President**  
Ingvar Ágúst Ingvarsson  
Reykjavik, Iceland



**Secretary**  
Kathleen Gallant  
Pittsburgh, USA



**Treasurer**  
Josef de Guzman  
Manila, Philippines



**Board Member**  
Silvia Fernandez Barrio  
Buenos Aires, Argentina



**Board Member**  
Masanori Okuse  
Yokohama, Japan



**Board Member**  
Helen Crawford  
Ottawa, Canada

# IFPA 2023

## Org no 802428-5986

### Profit and loss account

Income	2023-01-01 2023-12-31		2022-01-01 2022-12-31	
	SEK	EUR 11,096	SEK	EUR 11,1283
Membership fees	103 634	9 340	95 876	8 615
Rounding- off to whole SEK	-1	0	0	0
IFPA Conference	0	0	0	0
AbbVie	1 520 554	137 036	1 570 282	141 107
Almirall S.A.	1 260 589	113 608	1 296 026	116 462
Amgen	1 222 730	110 196	1 547 260	139 038
Boehringer Ingelheim	2 262 544	203 906	2 738 610	246 094
Bristol-Myers Squibb	1 243 615	112 078	1 735 803	155 981
Eli Lilly	1 206 722	108 753	1 139 029	102 354
Janssen	476 284	42 924	1 055 452	94 844
LEO Pharma A/S	1 185 734	106 861	1 101 240	98 959
Novartis	1 126 297	101 505	1 346 084	120 960
Pfizer	1 074 312	96 820	936 855	84 187
UCB	1 954 310	176 127	1 353 699	121 645
Other operating income	45 199	4 073	34 279	3 080
<b>Total income</b>	<b>15 146 156</b>	<b>1 365 010</b>	<b>15 950 495</b>	<b>1 433 327</b>



## Profit and loss account

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

Costs	SEK	EUR 11, 096	SEK	EUR 11, 1283
Outgoing donations	-1 361 496	-122 701	-224 511	-20 175
Translations	-116 410	-10 491	-227 715	-20 463
Member education	-8 612	-776		
Office rental agreement	-371 269	-33 460	-330 000	-29 654
Software programs	-170 679	-15 382	-161 181	-14 484
Freight and transport	-3 179	-287	-15 309	-1 376
Conference costs	-852 855	-76 861	-764 418	-68 691
Travel costs	-1 650 852	-148 779	-758 420	-68 152
Refund members	-303 721	-27 372	-214 489	-19 274
Hotel costs	-1 140 159	-102 754	-521 104	-46 827
Food	-140 384	-12 652	-191 585	-17 216
Reimbursement	-166 289	-14 986	-32 276	-2 900
Printing costs	-235 591	-21 232	-116 398	-10 460
PR-Marketing	-1 281 328	-115 477	-603 737	-54 252
News service, PR	-219 893	-19 817	-225 834	-20 294
Hospitality	-1 760	-159	-4 966	-446
Gifts	-7 594	-684	-5 099	-458
Office material	-178 117	-16 052	-62 790	-5 642
Phone	-32 455	-2 925	-30 234	-2 717
Insurance for the organization	-16 417	-1 480	-15 481	-1 391
Losses on receivables	-289	-26	-44 766	-4 023
Honorariums for external	-208 735	-18 812	-85 163	-7 653
Accountant and audit	-74 011	-6 670	-66 800	-6 003
Consultants	-1 976 180	-178 098	-2 856 842	-256 719
Web	-57 939	-5 222	-76 106	-6 839
IT-costs	-74 268	-6 693	-54 081	-4 860
Bank fees	-49 593	-4 469	-13 241	-1 190
Membership fees	-301 486	-27 171	-261 656	-23 513
Other operating expenses	1 652 505	148 928	-631 324	-56 731
Staff & Project management	-6 043 632	-544 668	-5 748 514	-516 567
Interest income tax and bank	10 366	934	28	3
Interest taxes and fees	-1 145	-103	-31 898	-2 866
Exchange profit/loss	63 984	5 766	24 324	2 186
<b>Total costs</b>	<b>-15 319 478</b>	<b>-1 380 631</b>	<b>-14 351 585</b>	<b>-1 289 648</b>
<b>Profit (+) / Loss (-)</b>	<b>-173 323</b>	<b>-15 620</b>	<b>1 598 910</b>	<b>143 680</b>

**Costs per activity**2023-01-01  
2023-12-312022-01-01  
2022-12-31

<b>20. Income</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Losses on receivables	0	0	-44 766	-4 023
Bank fees	-2 465	-222	-735	-66
Exchange profit/loss	20 653	1 861	92560	8 318
<b>Total costs</b>	<b>18 188</b>	<b>1 639</b>	<b>47 059</b>	<b>4 229</b>

<b>30. Governance</b>				
Software Programs	0	0	-2 728	-245
Freight and transport	0	0	-3 919	-352
Conference costs	-19 347	-1 744	-123 871	-11 131
Travel costs	-334 660	-30 160	-123 763	-11 121
Refund members	0	0	-119 691	-10 756
Hotel costs	-12 547	-1 131	-149 615	-13 445
Food	-7 655	-690	-96 330	-8 656
Reimbursement	-24 386	-2 198	-4 789	-430
Printing costs	-8 127	-732	-4 714	-424
Gifts	-413	-37	-1 599	-144
Office material	0	0	-11 888	-1 068
Phone	-3 484	-314	-2 221	-200
Insurance for the organization	-4 226	-381	-7 500	-674
Consultants	-8 752	-789	-134 857	-12 118
Bank fees	-332	-30	-868	-78
Membership fees	-24 838	-2 238	-13 007	-1 169
Staff & Project management	-241 209	-21 738	-5 968	-536
Exchange profit/ loss	566	51	254	23
<b>Total costs</b>	<b>-689 411</b>	<b>-62 131</b>	<b>-807 072</b>	<b>-72 524</b>



## Costs per activity

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

<b>40. Members</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Outgoing donations	-198 587	-17 897	-224 511	-20 175
Member education	-8 612	-776	0	0
Software programs	-139 037	-12 530	-56 815	-5 105
Office material	-138	-12	0	0
Phone	-580	-52	0	0
Conference costs	-140 816	-12 691	0	0
Travel costs	-139 598	-12 581	0	0
Refund members	-151 853	-13 685	0	0
Hotel costs	-127 394	-11 481	0	0
Food	-109 976	-9 911	0	0
Printing costs	-2 219	-200	-3 385	-304
Gifts	-483	-44	0	0
Consultants	-86 844	-7 827	0	0
Staff & Project management	-624 860	-56 314	-674 213	-60 585
Exchange profit/loss	361	33	-1 377	-124
<b>Total costs</b>	<b>-1 730 636</b>	<b>-155 969</b>	<b>-960 301</b>	<b>-86 294</b>

<b>45. Accelerator</b>				
Outgoing donations	-9 385	-846	0	0
Software programs	0	0	-46 375	-4 167
PR-Marketing	-137 471	-12 389		
News service, PR	0	0	-32 071	-2 882
Web	-1 220	-110	-163	-15
Other operating expenses	0	0	41 875	3 763
Staff & Project management	-360 400	-32 480	-265 770	-23 882
Exchange profit/loss	894	81		
<b>Total costs</b>	<b>-507 581</b>	<b>-45 744</b>	<b>-302 504</b>	<b>-27 183</b>



## Costs per activity

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

<b>50. Secretariat and Staff</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Office rental agreement	-371 269	-33 460	-330 000	-29 654
Software programs	-13 200	-1 190	-15 878	-1 427
Freight and transport	-1 251	-113	0	0
Conference costs	-39 247	-3 537	-28 607	-2 571
Travel costs	-6 308	-568	-24 894	-2 237
Hotel costs	-5 220	-470	-58 231	-5 233
Food	-2 617	-236	-9 888	-889
Printing costs	-3 567	-321	0	0
Hospitality	0	0	-213	-19
Gifts	0	0	-410	-37
Office material	-174 988	-15 770	-42 722	-3 839
Phone	-25 766	-2 322	-27 851	-2 503
Insurance for the organization	-12 191	-1 099	-7 981	-717
Accountant and audit	-74 011	-6 670	-66 800	-6 003
Consultants	-5000	-451	-57 069	-5 128
Web	0	0	-47 371	-4 257
IT-costs	-74 268	-6 693	-54 081	-4 860
Bank fees	-46 795	-4 217	-11 638	-1 046
Interest income tax and bank	10 366	934	28	3
Interest taxes and fees	-1 145	-103	-31 898	-2 866
Staff & Project management	-1 149 156	-103 565	-1 611 459	-144 807
Exchange profit/loss	58 105	5 237	-270	-24
<b>Total costs</b>	<b>-1 937 527</b>	<b>-174 615</b>	<b>-2 427 231</b>	<b>-218 113</b>

<b>60. Communication</b>				
Software programs	-9 657	-870	-39 196	-3 522
Freight and transport	-288	-26		
Travel costs	0	0	-3 782	-340
Hotel costs	0	0	-2 999	-270
Printing costs	-20 406	-1 839	-26 581	-2 389
PR-Marketing	-67 584	-6 091	-20 202	-1 815
News service, PR	-15 476	-1 395	-15 486	-1 392
Office material	0	0	-5 990	-538
Consultants	0	0	-71 625	-6 436
Web	-47 850	-4 312	-12 742	-1 145
Staff & Project management	-460 290	-41 483	-266 943	-23 988
Exchange profit/loss	-813	-73	-160	-14
<b>Total costs</b>	<b>-622 363</b>	<b>-56 089</b>	<b>-465 706</b>	<b>-41 849</b>



## Costs per activity

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

<b>65. World Psoriasis Day</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Translations	-2 147	-194	-42 792	-3 845
Conference costs	-129 675	-11 687	0	0
Travel costs	0	0	-4 275	-384
Hotel costs	0	0	-1 428	-128
Food	-1 520	-137	-1 282	-115
Printing costs	-83 451	-7 521	-10 716	-963
PR-Marketing	-103 547	-9 332	-263 694	-23 696
News service, PR	-64 929	-5 852	-76 809	-6 902
Office material	-222	-20	0	0
Honorariums for external	-27 323	-2 462	0	0
Consultants	-35 214	-3 174	-112 375	-10 098
Web	-4 260	-384	-11 286	-1 014
Staff & Project management	-499 999	-45 061	-485 807	-43 655
Exchange profit/loss	-1 761	-159	-989	-89
<b>Total costs</b>	<b>-954 048</b>	<b>-85 981</b>	<b>-1 011 453</b>	<b>-90 890</b>

<b>70. Advocacy &amp; Policy</b>				
Travel costs	-102 670	-9 253	-32 566	-2 926
Hotel costs	-146 519	-13 205	-15 937	-1 432
Food	-1 441	-130	-202	-18
Reimbursement	-20 016	-1 804	0	0
PR-Marketing	-95 334	-8 592	0	0
Hospitality	-1 658	-149	0	0
Phone	-987	-89	0	0
Membership fees	-276 648	-24 932	-243 270	-21 860
Staff & Project management	-469 267	-42 292	-381 935	-34 321
Exchange profit/loss	1 370	123	6 100	548
<b>Total costs</b>	<b>-1 113 169</b>	<b>-100 322</b>	<b>-667 809</b>	<b>-60 010</b>



## Costs per activity

2023-01-01  
2023-12-312022-01-01  
2022-12-31

71. IFPA Forum	SEK	EUR 11,096	SEK	EUR 11,1283
Translations	-103 213	-9 302	0	0
Software programs	0	0	-190	-17
Freight and transport	-1 641	-148	-8 261	-742
Conference costs	-168 561	-15 191	-60 715	-5 456
Travel costs	-266 561	-24 023	-187 784	-16 874
Refund members	-151 867	-13 687	-94 798	-8 519
Hotel costs	-257 468	-23 204	-81 167	-7 294
Food	0	0	-58 343	-5 243
Reimbursement	0	0	-4 789	-430
Printing costs	-67 351	-6 070	-45 061	-4 049
PR-Marketing	0	0	-96 585	-8 679
News service, PR	-22 317	-2 011	-33 822	-3 039
Gifts	-5 569	-502	-3 090	-278
Office material	-1 255	-113	-337	-30
Phone	-336	-30	0	0
Honorariums for external	-6 941	-626	0	0
Consultants	-439 801	-39 636	-870 365	-78 212
Web	-1 220	-110	-163	-15
Other operating expenses	0	0	85 937	7 722
Staff & Project management	-342 247	-30 844	-453 610	-40 762
Exchange profit/loss	-876	-79	-23 540	-2 115
<b>Total costs</b>	<b>-1 837 224</b>	<b>-165 575</b>	<b>-1 936 684</b>	<b>- 174 032</b>

75. IFPA Coalition				
Translations	-9 921	-894	-29 026	-2 608
Conference costs	-31 325	-2 823	-14 888	-1 338
Travel costs	-218 945	-19 732	-31 968	-2 873
Hotel costs	-67 456	-6 079	-10 882	-978
Food	-1 752	-158	-4 405	-396
Printing costs	-19 639	-1 770	0	0
News service, PR	-117 171	-10 560	-61 015	-5 483
Office material	-100	-9	0	0
Consultants	-1 051 690	-94 781	-738 888	-66 397
Web	-211	-19	-3 820	-343
Staff & Project management	-122 804	-11 067	-191 658	-17 223
Exchange profit/loss	-6 845	-617	-5 723	-514
<b>Total costs</b>	<b>-1 647 857</b>	<b>-148 509</b>	<b>-1 092 272</b>	<b>-98 153</b>



## Costs per activity

2023-01-01  
2023-12-312022-01-01  
2022-12-31

<b>80. Science</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Software programs	-1257	-113	0	0
Freight and transport	0	0	-481	-43
Conference costs	-148 155	-13 352	-356 403	-32 027
Travel costs	-523 882	-47 214	-149 657	-13 448
Hotel costs	-459 689	-41 428	-135 325	-12 160
Food	-15 211	-1 371	-7 999	-719
Reimbursement	-121 886	-10 985	-22 699	-2 040
Printing costs	0	0	-6 313	-567
Hospitality	-102	-9	-1 876	-169
Office material	-479	-43	-140	-13
Phone	-1 301	-117	-162	-15
Web	-236	-21	-211	-19
Staff & Project management	-570 161	-51 384	-646 007	-58 051
Exchange profit/loss	-697	-63	-534	-48
<b>Total costs</b>	<b>-1 843 056</b>	<b>-166 101</b>	<b>-1 327 807</b>	<b>-119 318</b>

<b>85. IFPA Conference / WPPAC</b>				
Software programs	-7 529	-679	0	0
Freight and transport	0	0	-642	-58
Conference costs	-141 843	-12 783	-4 000	-359
Travel costs	0	0	-8 244	-741
Food	-212	-19	-329	-30
Printing costs	-23 911	-2 155	-7 414	-666
PR-Marketing	-4 125	-372	-184 100	-16 543
News service, PR	0	0	-6 631	-596
Hospitality	0	0	-2 877	-259
Office material	-936	-84	-965	-87
Consultants	-135 159	-12 181	-81 250	-7 301
Web	-2 941	-265	-350	-31
Other operating expenses	930 298	83 841	627 922	56 426
Staff & Project management	-612 270	-55 179	-330 453	-29 695
Exchange profit/loss	-1 372	-124	-670	-60
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>



## Costs per activity

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

90. Projects	SEK	EUR 11,096	SEK	EUR 11,1283
Outgoing donations	-1 153 524	-103 959	0	0
Translations	-1 129	-102	-155 897	-14 009
Freight and transport	0	0	-2 006	-180
Conference costs	-33 887	-3 054	-175 934	-15 810
Travel costs	-58 228	-5 248	-191 488	-17 207
Hotel costs	-63 866	-5 756	-65 520	-5 888
Food	0	0	-12 808	-1 151
Printing costs	-6 919	-624	-12 214	-1 098
PR-Marketing	-873 267	-78 701	-39 156	-3 519
Gifts	-1 129	-102	0	0
Office material	0	0	-749	-67
Losses on receivables	-289	-26	0	0
Honorariums for external	-174 471	-15 724	-85 163	-7 653
Consultants	-213 719	-19 261	-790 412	-71 027
Membership fees	0	0	-5 380	-483
Other operating expenses	722 207	65 087	-1 387 058	-124 642
Project management	-590 969	-53 260	-434 692	-39 062
Exchange profit/loss	-5 603	-505	-41 326	-3 714
<b>Total costs</b>	<b>-2 454 794</b>	<b>-221 232</b>	<b>-3 399 802</b>	<b>-305 510</b>



## Balance sheet

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

<b>Bank assets and claims</b>	<b>Note</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Outstanding claims	1	3 853 093	347 251	4 501 344	404 495
Other claims		652	59	28	3
Prepaid expenses and accrued income	2	2 366 307	213 258	738 862	66 395
Cash		2665	240	2 623	236
Bank Nordea		8 004 726	721 406	14 157 762	1 272 230
<b>Total bank assets and claims</b>		<b>14 227 443</b>	<b>1 282 214</b>	<b>19 400 619</b>	<b>1 743 359</b>

2023-01-01  
2023-12-31

2022-01-01  
2022-12-31

<b>Capitals and creditors</b>	<b>Note</b>	SEK	EUR 11,096	SEK	EUR 11,1283
Capital		9 268 922	835 339	7 670 012	689 235
Profit or loss		-173 323	-15 620	1 598 910	143 680
Outstanding debts		174 346	15 713	108 870	9 783
Other debts		1 225 801	110 472	1 046 381	94 029
Prepaid income	3	2 620 141	236 134	7 049 705	633 493
Accrued costs and fees paid in advance	4	1 111 555	100 176	1 926 740	173 139
<b>Total capital and creditors</b>		<b>14 227 443</b>	<b>1 282 214</b>	<b>19 400 619</b>	<b>1 743 359</b>



## Notes

2023-01-01  
2023-12-312022-01-01  
2022-12-31

		SEK	EUR 11,096	SEK	EUR 11,1283
--	--	-----	---------------	-----	----------------

**Note 1 Outstanding claims**

UCB Biopharma		1 844 425	166 224	534 383	48 020
Amgen		1 295 566	116 760	1 206 722	108 437
Almirall		697 146	62 829	14 305	1 285
Bristol Myers Squibb		9 372	845	0	0
OPEN Health		3 384	305	0	0
Boehringer Ingelheim		3 200	288	2 500	225
AbbVie		0	0	1 520 554	136 638
Eli Lilly		0	0	1 206 722	108 437
SPOEX Iceland		0	0	6 132	551
CSN Canada		0	0	3 066	276
PsorPhil Philippines		0	0	2 873	258
Psoriasisliitto Finland		0	0	2 044	184
EUROPSO		0	0	2 044	184
<b>Total</b>		<b>3 853 093</b>	<b>347 251</b>	<b>4 501 344</b>	<b>404 495</b>



## Notes

2023-01-01  
2023-12-312022-01-01  
2022-12-31

		SEK	EUR 11,096	SEK	EUR 11,1283
--	--	-----	---------------	-----	----------------

**Note 2 Prepaid expenses and accrued income***Prepaid expenses*

IFPA Conference 2024		1 558 220	140 431	627 922	56 426
Helioworks Slottsbacken		108 750	9 801	82 500	7 414
Tranås resebyrå		85 464	7 702	0	0
Project Rare GPP		31 171	2 809	0	0
Ticketmaster		13 1320	1 182	0	0
AIG Europe		11 666	1 051	0	0
Membership GHC 2024		10 896	982	11 212	1 008
Membership IAPO 2024		4 389	396	8 779	789
Learnifier		4 375	394	0	0
Lisa Technologies		3 959	357	2 619	235
Fortnox		2 105	190	2 280	205
Scrive		2 063	186	2 063	185
Republic Factory		1 500	135	0	0
Söderberg & Partners Insurance Consulting		1 403	126	1 301	117
Loopia		0	0	186	17
		<b>1 839 081</b>	<b>165 743</b>	<b>738 862</b>	<b>66 395</b>

*Accrued income*

EUROPSO		221 500	19 962	0	0
Psoriasispatienten Nederland		130 766	11 785	0	0
SAPSA South Africa		72 828	6 563	0	0
FUNDAPSO Colombia		59 796	5 389	0	0
Shepard Exposition		20 524	1 850	0	0
Europeiska ERV		12 083	1 089	0	0
Nordea Bank Abp		9 728	877	0	0
		<b>527 226</b>	<b>47 515</b>	<b>0</b>	<b>0</b>
<b>Total</b>		<b>2 366 307</b>	<b>213 258</b>	<b>738 862</b>	<b>66 395</b>



## Notes

2023-01-01  
2023-12-312022-01-01  
2022-12-31

	SEK	EUR 11,096	SEK	EUR 11,1283
--	-----	---------------	-----	----------------

**Note 3 Prepaid income**

UCB Biopharma	1 224 190	110 327	1 332 125	119 706
Amgen	1 048 227	94 469	804 481	72 291
Takeda Pharmaceuticals	347 724	31 338	0	0
AbbVie	0	0	1 520 554	136 638
Bristol Myers Squibb	0	0	1 206 722	108 437
Eli Lilly	0	0	1 206 722	108 437
Novartis Pharma	0	0	979 101	87 983
<b>Total</b>	<b>2 620 141</b>	<b>236 134</b>	<b>7 049 705</b>	<b>633 493</b>

**Note 4 Accrued costs and fees received in advance***Accrued costs*

IFPA Projects	870 205	78 425	1 666 912	149 790
Last Mile	112 558	10 144	0	0
Hummelkläppen	51 000	4 596	45 000	4 044
Iriam Productions	30 000	2 704	30 000	2 696
Credit card purchases dec	18 556	1 672	180 861	16 252
Travel reimbursements	13 243	1 193	0	0
Nordea Bank Abp	4 886	440	0	0
Helioworks Slottsbacken	2 938	265	0	0
Tele2	2 601	234	0	0
Membership fee Italy 2022, to be returned	472	43	472	42
Fortnox	359	32	0	0
	<b>1 106 818</b>	<b>99 749</b>	<b>1 923 245</b>	<b>172 825</b>

*Fees received in advance*

Israel 2024	3 347	302	0	0
Uruguay 2024-2026	620	56	826	74
Kenya 2024-2025	494	45	741	67
Indonesia 2024	277	25	0	0
Singapore 2023	0	0	936	84
Malaysia 2023	0	0	506	46
Croatia 2023	0	0	258	23
Brazil 2023	0	0	227	20
	<b>4 737</b>	<b>427</b>	<b>3 495</b>	<b>314</b>
<b>Total</b>	<b>1 111 555</b>	<b>100 176</b>	<b>1 926 740</b>	<b>173 139</b>



## Signatures

Stockholm, June 25, 2024

Hoseah Waweru  
President, passed away on May 28, 2024

Ingvar Ingvarsson  
Acting President

Kathleen L Gallant  
Secretary

Josef de Guzman  
Treasurer

Silvia Fernandez Barrio  
Board Member

Masanori Okuse  
Board Member

Helen Crawford  
Board Member

My auditor's report has been issued on July 4, 2024

Hummelkläppen i Stockholm AB

Tommy Nilsson  
Authorized Public Accountant



Slottsbacken 8  
111 30 Stockholm, SWEDEN



[ifpa-pso.com](http://ifpa-pso.com)  
[info@ifpa-pso.com](mailto:info@ifpa-pso.com)



[@psoriasisIFPA](https://www.instagram.com/psoriasisIFPA)